In conclusion, this study illustrates that YXT ameliorates gut microbiota dysbiosis in rats with CHF, subsequently modulating serum BA levels and activating the BA receptor TGR5 to suppress inflammatory responses, thereby achieving therapeutic effects against CHF. This evidence concerns the gene GPBAR1 and congestive heart failure.